Proprietes biochimiques et biologiques des principaux facteurs de croissance; utilisation dans le domaine de la culture cellulaire animale; modeles in vitro pour les etudes pharmacologiques et toxicologiques et applications comme... more
Proprietes biochimiques et biologiques des principaux facteurs de croissance; utilisation dans le domaine de la culture cellulaire animale; modeles in vitro pour les etudes pharmacologiques et toxicologiques et applications comme medicaments
Research Interests: Pharmacology, Biochemistry, Physiology, Art, Toxicology, and 3 moreCell Culture, Application, and Entropie
Research Interests:
RGTAs, or ReGeneraTing Agents constitute a new class of medicinal substance that enhance both speed and quality of tissue healing and leading in some case to a real tissue regenerating process. RGTAs consist of chemically engineered... more
RGTAs, or ReGeneraTing Agents constitute a new class of medicinal substance that enhance both speed and quality of tissue healing and leading in some case to a real tissue regenerating process. RGTAs consist of chemically engineered polymers adapted to interact with and protect against proteolytic degradation of cellular signaling proteins known as growth factors, cytokines, interleukins, colony stimulating factors, chemokines, neurotrophic factors etc. Indeed almost all these proteins of cellular communication are naturally stored in the extra cellular matrix interacting specifically with the heparan sulfates or HS. After tissue injury of any cause, cells die liberating glycanases and proteases inducing first HS degradation then liberation of the cytokines which in turn are susceptible to degradation as they are no longer protected. By replacing the natural HS, RGTAs will protect cytokines from proteolyses as they are liberated from the matrix compartment matter in the wound. This ...
Research Interests:
This article summarizes some of the data that have been accumulated on several growth factors. Biochemical and biological properties of the Epidermal, Fibroblast, Astrocytes and Tumor growth factors (EGF, FGF, AGF, TGF) and those of... more
This article summarizes some of the data that have been accumulated on several growth factors. Biochemical and biological properties of the Epidermal, Fibroblast, Astrocytes and Tumor growth factors (EGF, FGF, AGF, TGF) and those of growth factors derived from Platelets (PDGF), Brain (BDGF, ECGF), Eye (EDGF) and Cartilage (CDGF) are reviewed, as well as the in vitro mechanism of action of EGF and PDGF. The in vivo effects of these growth factors, particularly the experiments achieved to understand the physiological or physiopathological significance are described. The potential interest of these molecules in pharmacology and their use as wound healing agents is discussed.
Research Interests:
Background: In recent clinical studies, growth factors have been used in both cardio-vascular and plastic surgery. We showed in a previous study that local administration of bFGF (basic Fibroblast Growth Factor), VEGF (vascular... more
Background: In recent clinical studies, growth factors have been used in both cardio-vascular and plastic surgery. We showed in a previous study that local administration of bFGF (basic Fibroblast Growth Factor), VEGF (vascular endothelial growth factor) and RGTA (regenerating agent), at the Latissimus Dorsi Muscle (LDM)-epicardial interface in a model of dynamic cardiomyoplasty, improved the vascularization and the trophicity of the LDM. In this study we compared two different methods of growth factor administra-tion. Methods: Right and left LDM flaps were performed in 24 sheep and left "in situ" in the thoracic wall. To create an ischemic environment, the serratus major was removed and the fascia was burned by electrocoagulation. Two different methods of growth factors admini-stration were used: topically on the LDM surface through a multiperforated catheter for weekly administration over a 1-month period, or intramuscularly (IM) during the proce-dure. Basic fibroblast g...
Page 1. FUNCTIONALIZED POLYMERS OF MALIC ACID STIMULATE TISSUE REPAIR PRESUMABLY BY REGULATING HEPARIN GROWTH FACTORS BIOAVAILABILITY 1Viviane Jeanbat-Mimaud, 2Christel Barbaud, 1Jean ...
Research Interests:
Using a rabbit anti-acidic fibroblast growth factor (anti-aFGF) antiserum, we tried to establish a precise mapping of aFGF localization in normal human ocular structures, from samples obtained by autopsies. Cell cultures of retinal... more
Using a rabbit anti-acidic fibroblast growth factor (anti-aFGF) antiserum, we tried to establish a precise mapping of aFGF localization in normal human ocular structures, from samples obtained by autopsies. Cell cultures of retinal pigment epithelium and ciliary pigment epithelium were also established and immunofluorescence studies were performed after 1 month. Corneal and conjunctival epithelia were strongly positive for anti-aFGF antibodies as well as the subcapsular epithelium of the lens. The cortical fibers were weakly reactive and the lens nucleus negative. A strong intracytoplasmic reactivity was observed in the pigmented and nonpigmented epithelial cells of ciliary processes and pars plana, both ex vivo and in vitro. Retina was brightly positive, mostly in the photoreceptor and plexiform layers. The possible involvement of aFGF in normal eye growth and in various ocular diseases was then discussed.
Research Interests: Biology, Ophthalmic, Medicine, Retinal Pigment Epithelium, Cell Culture, and 14 moreHumans, Retinal detachment, Retina, Fibroblast Growth Factor, Eye, Aged, Middle Aged, Fluorescent Antibody Technique, Optometry and Ophthalmology, Epithelium, Adult, Tissue distribution, Eye Diseases, and Fibroblast growth factors
Heparin has been shown to interact with acidic fibroblast growth factor (aFGF) and to potentiate the biological activity of aFGF on fibroblastic cells. Water-soluble dextran substituted with methyl carboxylic benzylamine and sulfonate... more
Heparin has been shown to interact with acidic fibroblast growth factor (aFGF) and to potentiate the biological activity of aFGF on fibroblastic cells. Water-soluble dextran substituted with methyl carboxylic benzylamine and sulfonate groups has been shown to mimic the effect of heparin in its anticoagulant and anticomplement activity. We have studied the effect of a dextran derivative named E (DDE), which had an anticoagulant activity equivalent to 0.5 IU heparin/mg, on the mitogenic activity of aFGF on Chinese hamster fibroblasts (CCL39). DDE interacts with aFGF in a comparable manner to heparin. We have shown that 20 micrograms of heparin or 400 micrograms of DDE added to 1 ml of culture medium has no effect on cell proliferation alone but potentiates the mitogenic activity of aFGF ten fold if aFGF is added at doses corresponding to half maximum stimulation (ED50). We have also studied the effect of various concentrations of heparin and DDE on the binding of 125I-aFGF on bovine brain membranes. Interestingly, the binding of 125I-aFGF increased three-fold as the concentration of heparin was increased up to 0.2 microgram/ml. At 1 microgram/ml of heparin, the amount of bound 125I-aFGF is comparable to that obtained in the absence of heparin. At higher concentrations, heparin displaces bound 125I-aFGF, and a 50% displacement is seen with 20 micrograms/ml of heparin. In the presence of DDE, no increase in 125I-aFGF binding is seen and a displacement is obtained with increasing doses. A possible explanation of these results may be the existence of specific receptors to heparin on the cellular membrane.(ABSTRACT TRUNCATED AT 250 WORDS)
Research Interests:
We have previously shown that only adult brain contained a detectable amount of high affinity receptors for basic Fibroblast growth factor (bFGF) whereas adult liver, kidney, lung, intestine or stomach showed only low affinity binding... more
We have previously shown that only adult brain contained a detectable amount of high affinity receptors for basic Fibroblast growth factor (bFGF) whereas adult liver, kidney, lung, intestine or stomach showed only low affinity binding sites. We now have studied and compared the distribution of the receptors for acidic Fibroblast growth factor (aFGF) with that of bFGF receptors in the same tissues. Membrane binding of 125I-aFGF was time dependent, reversible and displaced by an excess of unlabeled aFGF. Scatchard analyses of binding data obtained with all tissue membrane preparations revealed the presence of at least one class of low affinity/high capacity interaction sites characterized by apparent Kd values ranging from 3.9 to 6.9 x 10(-8) M. Interestingly and as for bFGF, high affinity receptors for aFGF could be detected only in adult brain membranes. Cross-linking and Scatchard analyses indicate that this family of interaction was characterized by four molecular species of 175, 125, 95 and 70 kDa and by an apparent Kd value of 1.8 x 10(-10) M. Moreover, cross-competition binding assay revealed that these brain high affinity receptors were common for both acidic and basic FGF. These results suggest that these growth factors may share identical functions mediated by the same receptors highly expressed in the brain. Using a cDNA probe for the Bek form of FGF receptors, we were able to show that all the tissues studied expressed this mRNA (4.5 kb transcript) but probably not in sufficient amounts to account for the number of high affinity receptors that we detected only in the brain.
Research Interests:
Research Interests: Ophthalmology, Electron Microscopy, Biology, Wound Healing, Transmission Electron Microscopy, and 14 moreCornea, Regeneration (Biology), Medicine, Female, Animals, Male, Retina, Cattle, Optometry and Ophthalmology, Epithelium, Rabbits, Neurosciences, Medical biochemistry and metabolomics, and Fibroblast growth factors
In previous work we have shown that some new regenerating agents (RGTAs), molecules which correspond to some dextran derivatives (DxD) containing defined amounts of carboxymethyl (CM), benzylamide (B) and benzylamide sulfonate (BS)... more
In previous work we have shown that some new regenerating agents (RGTAs), molecules which correspond to some dextran derivatives (DxD) containing defined amounts of carboxymethyl (CM), benzylamide (B) and benzylamide sulfonate (BS) groups, were able to stimulate tissue repair when applied at the site of injury. Based on in vitro studies showing that these DxD could interact and protect heparin binding growth factors (HBGFs), we postulated that DxD could also act in vivo by protecting endogenously released HBGFs against protease degradation. We now present data demonstrating that human plasmin (HP1), one of the known proteases involved in extracellular matrix remodelling and in the local activation of some growth factors is specifically inhibited by some specific DxD. The most efficient compounds for inhibiting the amidolytic activity were substituted by all functions with IC50 at 0.26 microM for RGTA11 (a DxD obtained from a 40,000 Da dextran containing 110% of CM, 2.5% of B and 36.5% of BS units and with IC50 at 1.1 microM for RGTA10 (derived from 10,000 Da dextran and containing 110% of CM, 0% of B and 27.3% of BS). Compounds which were substituted with only one or two functions were less effective. The degradation of FGF-2 by HP1 was analyzed by SDS-PAGE and by measuring its residual growth promoting activity using a bioassay on human skin fibroblasts. In this assay, RGTA11 at a concentration of 1 microM could inhibit by 80-100% FGF-2 degradation induced by HP1 treatment. In conclusion, the inhibitory activity of some DxD towards HP1 as well as the ability of these DxD to protect FGF-2 against this proteinase could partially explain its beneficial influence on extracellular matrix remodelling following tissue injury.
Research Interests:
Research Interests: Biochemistry, Biology, Medicine, Heparin, Animals, and 12 moreSodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis, Fibroblast Growth Factor, Affinity chromatography, Membrane, High Pressure Liquid Chromatography, Cattle, Biochimie, Receptor, Brain Chemistry, Biochemistry and cell biology, Heparan Sulfate, and Fibroblast growth factor receptor 3
Research Interests:
We report a series of 13 patients with COVID-19 treated with Cacipliq20®, an heparan sulfate mimetic approved for the treatment of hard to heal cutaneous ulcers. Heparan sulfates play important roles in tissue repair and possess antiviral... more
We report a series of 13 patients with COVID-19 treated with Cacipliq20®, an heparan sulfate mimetic approved for the treatment of hard to heal cutaneous ulcers. Heparan sulfates play important roles in tissue repair and possess antiviral activity. Cacipliq20® was administered through nebulization at a dose of 45 mg twice a day for 5.5 consecutive days. All patients presented respiratory symptoms with some dyspnea and in most cases pulmonary abnormalities on chest CT-Scan. Eight patients presented with a moderate form of the disease, three patients with a severe form, one with a mild form, and one with a critical form. In all patients the treatment was added to the standard of care. Ten patients were treated during the acute stage of the disease (<4 weeks from symptoms onset) while 3 patients were in the post-acute stage (>4 weeks from symptoms onset). A second treatment was administered for another 5.5 days in 6 patients. All patients showed clinically improvement after treat...
Research Interests:
Research Interests:
Research Interests:
ABSTRACT
Research Interests: Kinetics, Biology, Cell Biology, Medicine, Internalization, and 15 moreCell line, Mice, Endocytosis, Animals, Temperature, Fibroblast Growth Factor, Lung, Clinical Sciences, Fibroblast, Hamster, Human Fibroblasts, Recombinant Proteins, Biochemistry and cell biology, Chinese hamster, and Basic Fibroblast Growth Factor
Heparin affin regulatory peptide (HARP) composes, together with midkine (MK), a new family of heparin-binding growth/differentiation factors. Recently, HARP was incriminated in cancer progression, as an angiogenic factor and as a tumor... more
Heparin affin regulatory peptide (HARP) composes, together with midkine (MK), a new family of heparin-binding growth/differentiation factors. Recently, HARP was incriminated in cancer progression, as an angiogenic factor and as a tumor growth factor. In this study, we analyzed the possible involvement of HARP in human prostate cancer (Pca). The localization of HARP protein and its mRNAs in normal prostate (n = 5), benign prostate hyperplasia (BPH) (n = 7), and prostate cancer (Pca) (n = 9) was analyzed by immunohistochemistry and in situ hybridization. The mitogenic activity of this growth factor for prostate epithelial cells was determined with a thymidine incorporation assay. HARP cDNA was transfected into normal prostate epithelial (PNT-1A) cells, and their growth was evaluated by soft-agar growth assay. We found HARP protein associated with epithelial cells in PCa but not in normal prostate or BPH, while the corresponding mRNAs were located in the stromal compartment. Furthermore, HARP is mitogenic for PNT-1A, LNCaP, and DU-145 cells. Overexpression of the human HARP in PNT-1A transfected cells induced both anchorage-independent growth and growth at low serum concentrations. Our results suggest that HARP may act in a paracrine manner from mesenchymal to tumoral epithelial cells, and may play a role in the molecular mechanisms that regulate prostate tumor cell growth.
Research Interests:
Research Interests:
We have studied the endothelialization of polyethylene terephtalate (PET) prostheses coated with collagen by adult human saphenous endothelial cells (EC) under various in vitro conditions. Collagenous PET was impregnated either by... more
We have studied the endothelialization of polyethylene terephtalate (PET) prostheses coated with collagen by adult human saphenous endothelial cells (EC) under various in vitro conditions. Collagenous PET was impregnated either by Fibroblast Growth Factor 2 (FGF2), heparin, a synthetic heparan sulfate mimic named RGTA 11 (for ReGeneraTing Agent), or combinations of these products. RGTA 11 belongs to a new family of drugs, which have been previously described as stabilizer and protector of heparin binding growth factors (HBGF), and to act in vivo as to stimulate wounded tissue repair. As endothelialization of prosthesis can be obtained in vivo after EC seeding and/or by transanastomotic, as well as by transprosthetic EC migrations, we have designed in vitro models to study the growth of EC seeded on PET, the EC colonization of an acellular area on PET, and the migration of EC from a collagen gel through the prosthesis. The combinations of either RGTA11 or heparin with FGF2 enhanced after a week by 5-fold the growth of seeded EC compared to RGTA or heparin alone and by 3-fold compared to FGF2 alone (p &lt; 0.05). More than 80% of the colonization of an acellular area was achieved within 6 days when FGF2 was combined with RGTA11 or heparin. In contrast, colonization was only of 20% promoted in presence of FGF2 alone and not promoted in the presence of RGTA or heparin alone (p &lt; 0.05). In addition, transprosthetic migration of EC and endothelialization of the luminal side were observed only when gel contained RGTA11 or heparin in combination with FGF2. The present work did strongly indicate that RGTA11 could be used in vivo as to improve endothelialization and should be the focus of continued investigation.
Research Interests: Materials Science, Biomedical Engineering, Cell Division, Colonization, In Vitro, and 15 moreHumans, Heparin, Colonisation, Collagen, Biomedical Materials, Anticoagulants, Fibroblast Growth Factor, Glycosaminoglycan, Gels, In Vivo, Adult, Endothelial cell, Materials Testing, Carbohydrate Sequence, and Heparan Sulfate
Research Interests:
Research Interests:
Background CACIPLIQ20 (OTR3, Paris, France) is a medical device used for the treatment of chronic skin ulcers. It contains a heparan sulfate mimetic that accelerates tissue healing by stabilizing matrix proteins and protecting... more
Background CACIPLIQ20 (OTR3, Paris, France) is a medical device used for the treatment of chronic skin ulcers. It contains a heparan sulfate mimetic that accelerates tissue healing by stabilizing matrix proteins and protecting heparin-binding growth factors. In humans, an open self-controlled study suggested that the topical application of CACIPLIQ20 optimizes skin healing following surgery. Objectives To expand previous findings using a different CACIPLIQ20 administration regimen. Methods Twenty-four females were referred for breast-reduction surgery. Each patient had their own control with 1 CACIPLIQ20-treated and 1 saline-treated control breast. The treated side (right or left) was randomly assigned by the operating surgeon. Scar appearance was assessed by 6 independent raters using a global visual scar comparison scale based on scar photographs. All raters were blinded toward the CACIPLIQ20-treated side. Results The follow-up period following surgery ranged from 1 to 12 months w...
Research Interests:
HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or... more
HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés. Eye-derived fibroblast growth factors: receptors and early events studies Michel Moenner, Josette Badet, Bertrand Chevallier, M Tardieu, J. Courty, Denis Barritault
Research Interests:
Research Interests:
Research Interests:
Research Interests:
HARP (heparin affin regulatory peptide), also called pleiotrophin (PTN), belongs to the heparin binding growth factors (HBGFs) family. Several new data suggest a role for HARP during the various stages of angiogenesis. In vivo, HARP is... more
HARP (heparin affin regulatory peptide), also called pleiotrophin (PTN), belongs to the heparin binding growth factors (HBGFs) family. Several new data suggest a role for HARP during the various stages of angiogenesis. In vivo, HARP is localised in endothelial cells of blood capillaries. In vitro, HARP displays mitogenic activity on endothelial cells, induces the formation of capillary-like structures in collagen gel, and degrades extracellular matrix via stimulation of plasminogen activator activity. HARP is also involved in neoangiogenesis during tumor progression. This review discusses the possible role of HARP in tumor angiogenesis and its therapeutic implications.
Research Interests:
Angiogenin is a potent blood-vessel-inducing polypeptide with a molecular weight of 14,000 that has a unique ribonucleolytic activity. First isolated from the conditioned medium of tumour cells, angiogenin has since been purified from... more
Angiogenin is a potent blood-vessel-inducing polypeptide with a molecular weight of 14,000 that has a unique ribonucleolytic activity. First isolated from the conditioned medium of tumour cells, angiogenin has since been purified from normal plasma, which suggested that its propensity to induce neovascularization should be strictly controlled. Modulation of that activity might involve interaction of angiogenin with cell-surface receptors and extracellular matrix of endothelial cells, tight-binding inhibition of both its ribonucleolytic activity and cell binding property by ribonuclease inhibitor, as well as the overall influence of divalent copper, a modulator of angiogenesis.
Research Interests:
Research Interests:
Research Interests:
The placenta has been shown to contain bFGF, but the presence of specific binding sites for this growth factor in this tissue remained to be established. In order to study the role of bFGF in the placenta growth, we looked for specific... more
The placenta has been shown to contain bFGF, but the presence of specific binding sites for this growth factor in this tissue remained to be established. In order to study the role of bFGF in the placenta growth, we looked for specific binding sites on mouse placental cell membranes at days 12, 14, 16, and 18 of pregnancy. At day 12, Scatchard analyses indicated that two classes of specific interaction sites for bFGF were detected. One class of high affinity binding sites was characterized by an apparent Kd of 10 pM and a binding capacity of 10 fmoles per mg of membrane protein. A second class of low affinity binding sites was detected with an apparent Kd of 60 nM and a binding capacity of 26 pmoles per mg of membrane protein. At days 14, 16 or 18, Scatchard analyses only showed low affinity binding sites with an apparent Kd of 24 nM and a binding capacity of 230 pmoles per mg of membrane protein. The characterization of these binding sites was performed by cross linking experiments that revealed two forms of specific complexes. This result suggested that the high affinity binding sites correspond to putative receptors with relative molecular masses equal to 65,000 and 85,000. The dramatic decrease of the high affinity receptor number after the 12th day of pregnancy, which is synchronous with the 9-fold increase of the low affinity binding site number, suggests that the biological activity of bFGF could be regulated by a balance between both the numbers of high and low affinity binding sites on placenta cell membranes. Thus, as it was shown for other growth factors, bFGF could only be involved at specific pregnancy stages.
Research Interests:
Research Interests:
Research Interests:
The aim of this study is to optimize conditions for growing endothelial cells on vascular biomaterials. Bovine cornea endothelial cells (BCEC), stimulated by basic Fibroblast Growth Factor (bFGF) secrete an extracellular matrix (ECM)... more
The aim of this study is to optimize conditions for growing endothelial cells on vascular biomaterials. Bovine cornea endothelial cells (BCEC), stimulated by basic Fibroblast Growth Factor (bFGF) secrete an extracellular matrix (ECM) similar to the Descemet membrane produced in vivo by these cells. This ECM, obtained by removing BCEC with an hypotonic shock can be used as a substratum for other endothelial cell growth. Human endothelial cells (HEC) were purified from omentum that was digested with a solution of collagenase-dispase, then filtered through nylon meshes. The cells were further purified by centrifugation onto a Percoll gradient. A comparative study on the attachment and growth of HEC on various coatings (laminin, poly-L-lysine, fibronectin or ECM) indicates that ECM is the most performing substratum. The quality of this endothelium was confirmed by the presence of factor VIII, and MHC class I and the absence of class II antigens.
Research Interests:
Research Interests:
Research Interests:
Research Interests: Biology, Cell Biology, Biological Chemistry, Medicine, Signal Transduction, and 14 moreBiological Sciences, Cell Differentiation, Protein Kinases, Animals, Biological, Neurons, Fibroblast Growth Factor, Mitogen Activated Protein Kinase, CHEMICAL SCIENCES, Neuronal Differentiation, Rats, Nerve Growth Factor, Medical and Health Sciences, and Fibroblast growth factor receptor 3
Research Interests:
Research Interests:
Research Interests:
BackgroundAcute respiratory distress syndrome (ARDS) can be related to airway remodeling caused by pulmonary fibrosis and systemic inflammation. Etiologies of ARDS are multifaceted such as idiopathic pulmonary fibrosis or as recently the... more
BackgroundAcute respiratory distress syndrome (ARDS) can be related to airway remodeling caused by pulmonary fibrosis and systemic inflammation. Etiologies of ARDS are multifaceted such as idiopathic pulmonary fibrosis or as recently the SARS-CoV-2 infection. Antifibrotic drugs may be a better approach to slow the fibrotic process but they often have poor efficacy in patients, and the mortality rate remains high, up to 40% within 5 years of diagnosis.Here, we tested the antifibrotic effect of a ReGeneTaring Agents named OTR4120 in a bleomycin-induced mouse model of pulmonary fibrosis.MethodsSwiss mice were randomly divided into four experimental groups: saline-treated control group, an OTR4120 group, a bleomycin-induced fibrosis group without OTR4120, and a bleomycin-induced fibrosis groups with OTR4120 (intravenous injections every 3 days starting at day 11 post bleomycin I.P. injection). Lungs were compared using the lung/body weight index, and the extend of interstitial injury ar...
Research Interests:
Research Interests: Pathology, Biology, Immunohistochemistry, Medicine, Peroxidase, and 15 moreCell line, Bladder Cancer, Humans, Mice, Animals, Fibroblast Growth Factor, Clinical Sciences, Epithelium, Urological Cancer, Cell Proliferation, Growth Factor, Immunostaining, Transitional Cell Carcinoma, Nude mice, and Urinary bladder neoplasms
Heparin affin regulatory peptide (HARP) composes, together with midkine (MK), a new family of heparin-binding growth/differentiation factors. Recently, HARP was incriminated in cancer progression, as an angiogenic factor and as a tumor... more
Heparin affin regulatory peptide (HARP) composes, together with midkine (MK), a new family of heparin-binding growth/differentiation factors. Recently, HARP was incriminated in cancer progression, as an angiogenic factor and as a tumor growth factor. In this study, we analyzed the possible involvement of HARP in human prostate cancer (Pca). The localization of HARP protein and its mRNAs in normal prostate (n = 5), benign prostate hyperplasia (BPH) (n = 7), and prostate cancer (Pca) (n = 9) was analyzed by immunohistochemistry and in situ hybridization. The mitogenic activity of this growth factor for prostate epithelial cells was determined with a thymidine incorporation assay. HARP cDNA was transfected into normal prostate epithelial (PNT-1A) cells, and their growth was evaluated by soft-agar growth assay. We found HARP protein associated with epithelial cells in PCa but not in normal prostate or BPH, while the corresponding mRNAs were located in the stromal compartment. Furthermore, HARP is mitogenic for PNT-1A, LNCaP, and DU-145 cells. Overexpression of the human HARP in PNT-1A transfected cells induced both anchorage-independent growth and growth at low serum concentrations. Our results suggest that HARP may act in a paracrine manner from mesenchymal to tumoral epithelial cells, and may play a role in the molecular mechanisms that regulate prostate tumor cell growth.